What genetic variants are associated with Cardiovascular Disease (Genetic Risk)?

Key pharmacogenomic variants: rs7412 in APOE, rs699 in AGT, rs5186 in AGTR1. Genes involved: APOE, AGT, AGTR1, PCSK9, LDLR.

How can PepFold help with Cardiovascular Disease (Genetic Risk) research?

PepFold accepts the rsIDs associated with Cardiovascular Disease (Genetic Risk) (rs7412, rs699, rs5186) and generates computational peptide candidates targeting the affected proteins. Each candidate comes with predicted 3D structures, 10-dimension scoring, and Fmoc-SPPS synthesis protocols.

Condition Database

Cardiovascular Disease (Genetic Risk)

Prevalence: Leading cause of death globally: 17.9 million deaths/year (WHO 2023)

Genetic variants in APOE, AGT, AGTR1, and lipid metabolism genes contribute to cardiovascular risk. Pharmacogenomics guides anticoagulant, antiplatelet, and antihypertensive therapy selection.

Peptide Therapeutics

PCSK9 inhibitor peptides, angiotensin-targeting peptides, natriuretic peptide analogs (nesiritide), antiplatelet peptides (eptifibatide), and APOE-modulating peptides for lipid management.

Current Treatments

Statins, PCSK9 antibodies (evolocumab, alirocumab), ACE inhibitors, ARBs, antiplatelet agents, anticoagulants.

Key Genetic Variants

rs7412~8% global allele frequency

APOE — APOE2 (Arg158Cys)

rs699~42% global (Thr allele)

AGT — Met235Thr

rs5186~30% global (C allele)

AGTR1 — A1166C

Associated Genes

APOEApolipoprotein E

Lipid transport, cholesterol metabolism, neuronal repair, and amyloid-beta clearance in the brain. APOE is the major genetic risk modulator for late-onset Alzheimer's disease.

AGTProfile coming soon

AGTR1Profile coming soon

PCSK9Profile coming soon

LDLRProfile coming soon

Explore peptide candidates for Cardiovascular Disease (Genetic Risk)

Submit rs7412, rs699, rs5186 to PepFold. Full report with 3D structures and synthesis protocols in under 2 minutes.

Try Analysis View Pricing